New drug combo aims to prevent deadly transplant complication in rare blood cancer
NCT ID NCT07440654
First seen Mar 01, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study tests whether a new drug called gecacitinib, combined with standard therapy, can prevent acute graft-versus-host disease (aGVHD) in people with myelofibrosis who receive a stem cell transplant. About 40 adults will take part. The goal is to see if the drug reduces severe immune reactions after transplant, while also improving blood cell recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGVHD PROPHYLAXIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.